BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17531261)

  • 1. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis.
    Bracher M; Gould HJ; Sutton BJ; Dombrowicz D; Karagiannis SN
    J Immunol Methods; 2007 Jun; 323(2):160-71. PubMed ID: 17531261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.
    Karagiannis SN; Bracher MG; Beavil RL; Beavil AJ; Hunt J; McCloskey N; Thompson RG; East N; Burke F; Sutton BJ; Dombrowicz D; Balkwill FR; Gould HJ
    Cancer Immunol Immunother; 2008 Feb; 57(2):247-63. PubMed ID: 17657488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
    Karagiannis SN; Bracher MG; Hunt J; McCloskey N; Beavil RL; Beavil AJ; Fear DJ; Thompson RG; East N; Burke F; Moore RJ; Dombrowicz DD; Balkwill FR; Gould HJ
    J Immunol; 2007 Sep; 179(5):2832-43. PubMed ID: 17709497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells.
    Flieger D; Gruber R; Schlimok G; Reiter C; Pantel K; Riethmüller G
    J Immunol Methods; 1995 Mar; 180(1):1-13. PubMed ID: 7897241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
    Karagiannis P; Singer J; Hunt J; Gan SK; Rudman SM; Mechtcheriakova D; Knittelfelder R; Daniels TR; Hobson PS; Beavil AJ; Spicer J; Nestle FO; Penichet ML; Gould HJ; Jensen-Jarolim E; Karagiannis SN
    Cancer Immunol Immunother; 2009 Jun; 58(6):915-30. PubMed ID: 18941743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
    Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
    Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.
    Gould HJ; Mackay GA; Karagiannis SN; O'Toole CM; Marsh PJ; Daniel BE; Coney LR; Zurawski VR; Joseph M; Capron M; Gilbert M; Murphy GF; Korngold R
    Eur J Immunol; 1999 Nov; 29(11):3527-37. PubMed ID: 10556807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity.
    Kramski M; Schorcht A; Johnston AP; Lichtfuss GF; Jegaskanda S; De Rose R; Stratov I; Kelleher AD; French MA; Center RJ; Jaworowski A; Kent SJ
    J Immunol Methods; 2012 Oct; 384(1-2):51-61. PubMed ID: 22841577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
    Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
    Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
    Klöss S; Bochennek K; Huenecke S; Zimmermann SY; Kuçi S; Müller T; Wels WS; Klingebiel T; Esser R; Koehl U
    J Immunol Methods; 2007 Aug; 325(1-2):140-7. PubMed ID: 17663991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
    Mezzanzanica D; Canevari S; Colnaghi MI
    Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric mast cell-mediated cytotoxicity assay: a three-color flow cytometric approach using monoclonal antibody staining with annexin V/propidium iodide co-labeling to assess human mast cell-mediated cytotoxicity by fluorosphere-adjusted counts.
    Ozdemir O
    J Immunol Methods; 2011 Feb; 365(1-2):166-73. PubMed ID: 21215748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide.
    Lee-MacAry AE; Ross EL; Davies D; Laylor R; Honeychurch J; Glennie MJ; Snary D; Wilkinson RW
    J Immunol Methods; 2001 Jun; 252(1-2):83-92. PubMed ID: 11334968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies.
    Guyre CA; Gomes D; Smith KA; Kaplan JM; Perricone MA
    J Immunol Methods; 2008 Apr; 333(1-2):51-60. PubMed ID: 18314132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
    Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
    J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
    Varughese J; Cocco E; Bellone S; Bellone M; Todeschini P; Carrara L; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Gynecol Oncol; 2011 Jul; 122(1):171-7. PubMed ID: 21453957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity.
    Alrubayyi A; Schuetz A; Lal KG; Jongrakthaitae S; Paolino KM; Ake JA; Robb ML; de Souza MS; Michael NL; Paquin-Proulx D; Eller MA
    J Immunol Methods; 2018 Nov; 462():74-82. PubMed ID: 30148978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.